Your Health, We Care
Avoid concomitant use with strong CYP3A inhibitors. If concomitant use is unavoidable, reduce the dose of capmatinib and monitor the patient for adverse reactions.
When used concomitantly with moderate CYP3A inhibitors, reduce the dose of capmatinib and monitor the patient for adverse reactions.
Avoid concomitant use of capmatinib with strong or moderate CYP3A inducers.
from FDA，2024.09
As a novel AKT inhibitor, the drug interactions of capivasertib represent a critical aspect that mus···【more】
Recommended：302026-13-01
Although capivasertib offers a new treatment option for specific cancers, its efficacy and safety ar···【more】
Recommended：292026-13-01
As a novel AKT inhibitor, the drug interactions of capivasertib represent a critical aspect that must be prioritized in clinical practice.Which Drugs Interact with Capivasertib?Con···【more】
Article source：Lucius LaosRelease date：2026-01-13Recommended：30
Although capivasertib offers a new treatment option for specific cancers, its efficacy and safety are highly susceptible to the impact of concomitant medications, making it crucial···【more】
Article source：Lucius LaosRelease date：2026-01-13Recommended：29
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
